Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors-Reference-Cited by-同舟云学术

Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors

Published:2015-03 Issue:3 Volume:45 Page:310-318
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Segan J.¹²,Staples M. P.¹²,March L.³,Lassere M.⁴,Chakravarty E. F.⁵,Buchbinder R.¹²

Affiliation:

1. Department of Epidemiology and Preventive Medicine; School of Public Health and Preventive Medicine; Monash University; Melbourne Victoria Australia

2. Monash Department of Clinical Epidemiology; Cabrini Institute; Melbourne Victoria Australia

3. Institute of Bone and Joint Research; The University of Sydney; Floronce and Cope Professorial Department of Rheumatology; Royal North Shore Hospital; Sydney New South Wales Australia

4. St George Hospital; University of New South Wales; Sydney New South Wales Australia

5. Oklahoma Medical Research Foundation; Oklahoma City Oklahoma USA

Funder

Commonwealth Government of Australia National Health and Medical Research Council

Monash University

The Australian Rheumatology Association

Abbott Australia

Pfizer Australia

Janssen Australia

Sanofi Aventis

Amgen

Wyeth

Schering-Plough and Roche

Australian NHMRC

Oklahoma Centre for Advancement of Science and Technology

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.12679/fullpdf

Reference32 articles.

1. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA;Nam;Ann Rheum Dis,2010

2. Biologics for rheumatoid arthritis: an overview of Cochrane reviews;Singh;Cochrane Database Syst Rev,2009

4. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy;Yazici;Bull NYU Hosp Jt Dis,2008

5. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly;Galloway;Rheumatology (Oxford),2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus;Expert Opinion on Pharmacotherapy;2023-03-28

2. Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults;Rheumatology;2021-09-26

3. Risk factors for herpes zoster in patients with rheumatic diseases: a nationwide cohort study in Korea;Rheumatology;2020-11-24

4. Concomitant herpes simplex keratitis and autoimmune-associated ulcerative keratitis in rheumatoid arthritis patients;American Journal of Ophthalmology Case Reports;2020-06

5. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD;RMD Open;2019-09